S907
Clinical - Mixed sites & palliation
ESTRO 2026
directed therapy and were admitted with neurological symptoms had higher discontinuation rates. These findings emphasize careful consideration of treatment indication and the need for closer monitoring to reduce interruptions and optimize treatments. Keywords: radiotherapy interruption, hospitalization
collected. RT-related variables were also recorded including treatment status and intent, cumulative dose at admission, interruptions, duration, and permanent discontinuation. Descriptive and analytical statistics were performed, with significance set at p < 0.05. Results: A total of 264 patients were included. Their clinical characteristics, reason for admission and location RT are summarized in Table 1. At admission, 163 (61.7%) were awaiting RT, 41 (15.5%) were undergoing treatment, and 60 (22.7%) had completed therapy. Palliative intent predominated (59.1%), followed by radical (30.3%) and adjuvant (10.2%). Median planned RT sessions were 10 (IQR 5–25). The descriptive relationships between these variables are shown in Table 2.Among patients receiving active RT, median cumulative dose at admission was 24.6 Gy (IQR 12.25– 40.60). Treatment interruptions occurred in 64.9%, median duration 6.5 days (IQR 1.0–14.0). Interruption was significantly associated with male sex (p = 0.02), lung cancer (p = 0.040), stage IV disease (p = 0.015), and borderline significance for palliative intent (p = 0.057). No association was found with reason for admission (p = 0.28) or dose at admission (p = 0.075).In patients with pending RT, treatment withdrawal occurred in 18 cases, whereas in those with ongoing RT, permanent discontinuation occurred in 14. Both were significantly associated with CNS-targeted RT (p = 0.020) and neurological symptoms as the reason for admission (p = 0.035).
Mini-Oral 3907
Re-irradiation with proton therapy: quality of life in patients enrolled in the power registry at the European Institute of Oncology Martina Benincasa 1,2 , Daniela Alterio 1 , Maria Giulia Vincini 1 , Ilaria Repetti 1 , Chiara Lorubbio 1 , Salvatore Biagio Valia 1 , Roberta Ugolini 1 , Sara Ramella 2,3 , Barbara Alicja Jereczek-Fossa 1,4 1 Division of Radiation Oncology, European Institute of Oncology, Milan, Italy. 2 Research Unit of Radiation Oncology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy. 3 Research Unit of Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy. 4 Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
Purpose/Objective: Proton beam therapy (PBT) offers dosimetric
advantages in reirradiation (reRT) by reducing dose to organs at risk. This study prospectively evaluated HRQoL in patients undergoing PBT reRT at the European Institute of Oncology (IEO), Milan, Italy. Material/Methods: This prospective, longitudinal, single-centre study included patients treated between November 2023 and March 2025 who completed at least one HRQoL questionnaire. Exclusion criteria were absence of reRT, language barriers, and palliative-intent PBT. HRQoL was assessed using the EORTC QLQ-C30 (v3.0) at baseline, end of treatment, and 3 and 6 months post- PBT. Global Health Status (GHS), functional and symptom scales were analysed overall and by disease site (breast, prostate, head and neck, miscellaneous). All patients have been enrolled in the Power Registry (NCT05860361) Results:
Conclusion: Advanced stage and lung cancer increased the risk of treatment interruption in patients undergoing RT. Patients awaiting or undergoing RT, who received CNS-
Made with FlippingBook - Share PDF online